The Anti-Kickback Statute and the False Claims Act have become mainstays in the Department of Justice's and qui tam whistleblowers' arsenal of health care fraud enforcement tools. AKS cases consistently form a sizeable chunk of the Department of Justice's annual health care fraud recoveries. According to a recent estimate, between 2006 and 2022, the DOJ recovered over $29 billion in settlements against pharmaceutical manufacturers—a discrete but significant portion of the constellation of health services providers—alone. The change in presidential administration is unlikely to change the DOJ's focus in this area.